HK1202418A1 - Drug delivery system for sustained delivery of bioactive agents - Google Patents
Drug delivery system for sustained delivery of bioactive agentsInfo
- Publication number
- HK1202418A1 HK1202418A1 HK15102889.3A HK15102889A HK1202418A1 HK 1202418 A1 HK1202418 A1 HK 1202418A1 HK 15102889 A HK15102889 A HK 15102889A HK 1202418 A1 HK1202418 A1 HK 1202418A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bioactive agents
- sustained
- delivery system
- drug delivery
- delivery
- Prior art date
Links
- 239000012867 bioactive agent Substances 0.000 title 1
- 238000012377 drug delivery Methods 0.000 title 1
- 230000002459 sustained effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20116138A FI130619B (fi) | 2011-11-15 | 2011-11-15 | Matriisi bioaktiivisten aineiden hallittuun vapauttamiseen |
PCT/FI2012/051121 WO2013072563A1 (en) | 2011-11-15 | 2012-11-15 | Drug delivery system for sustained delivery of bioactive agents |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1202418A1 true HK1202418A1 (en) | 2015-10-02 |
Family
ID=47351708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102889.3A HK1202418A1 (en) | 2011-11-15 | 2015-03-23 | Drug delivery system for sustained delivery of bioactive agents |
Country Status (6)
Country | Link |
---|---|
US (1) | US11389537B2 (fi) |
EP (1) | EP2779996B1 (fi) |
JP (1) | JP6178329B2 (fi) |
FI (1) | FI130619B (fi) |
HK (1) | HK1202418A1 (fi) |
WO (1) | WO2013072563A1 (fi) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI125942B (fi) | 2013-07-26 | 2016-04-15 | Upm Kymmene Corp | Nanofibrilliselluloosakoostumuksen modifiointimenetelmä |
FI126120B (fi) | 2014-12-22 | 2016-06-30 | Upm Kymmene Corp | Prosessi hapetetun nanofibrilliselluloosan hydrogeelin tuottamiseksi |
FI125882B (fi) | 2014-12-22 | 2016-03-31 | Upm Kymmene Corp | Nanofibrilliselluloosan hydrogeelin lämpökäsittely |
FI125883B (fi) | 2014-12-22 | 2016-03-31 | Upm Kymmene Corp | Katalyyttisesti hapetetun nanofibrilliselluloosan hydrogeelin käsittely |
FI127834B (fi) * | 2015-06-04 | 2019-03-29 | Upm Kymmene Corp | Prosessi nanofibrilliselluloosan hydrogeelin tuottamiseksi |
US11173130B2 (en) * | 2015-09-24 | 2021-11-16 | Massachusetts Eye And Ear Infirmary | Drug delivery system and methods of use |
WO2017123577A1 (en) * | 2016-01-12 | 2017-07-20 | Repros Therapeutics Inc. | Trans-clomiphene and progesterone receptor antagonist combination therapy for treating hormone-dependent conditions |
JP7035006B2 (ja) * | 2016-07-08 | 2022-03-14 | セルテック アーベー | 多孔性固体材料がクローズドセルを含む、セルロースナノファイバー(cnf)を含む多孔性固体材料の薬物担体 |
CN113686794A (zh) * | 2016-08-08 | 2021-11-23 | 日本制纸株式会社 | 纤维素纳米纤维分散液的评价方法、纤维素纳米纤维水分散液、食品、化妆品和橡胶组合物 |
EP3335696B1 (en) * | 2016-12-15 | 2019-12-18 | UPM-Kymmene Corporation | A method for drying cell-free tissue extract in a hydrogel comprising nanofibrillar cellulose and a dried hydrogel comprising nanofibrillar cellulose and cell-free tissue extract |
DK3335695T3 (da) * | 2016-12-15 | 2020-04-20 | Upm Kymmene Corp | Fremgangsmåde til frysetørring af hydrogel omfattende nanofibrillær cellulose, frysetørret medicinsk hydrogel omfattende nanofibrillær cellulose og hydrogel omfattende nanofibrillær cellulose |
WO2019108887A1 (en) * | 2017-11-30 | 2019-06-06 | Warner Babcok Institute For Green Chemistry, Llc | Products comprising plant-based micro fibers |
KR102200787B1 (ko) * | 2017-12-29 | 2021-01-12 | 한경대학교 산학협력단 | 나노셀룰로오스를 이용한 습윤성 탄력붕대 |
EP3616730A1 (en) | 2018-08-28 | 2020-03-04 | UPM-Kymmene Corporation | Composition or matrix for storage of bacteriophages comprising nanofibrillar cellulose |
JP7147490B2 (ja) * | 2018-11-07 | 2022-10-05 | 凸版印刷株式会社 | 徐放性複合粒子、徐放性複合粒子の製造方法及び乾燥粉体 |
HUP1900226A1 (hu) * | 2019-06-21 | 2020-12-28 | Hummel Zoltan Dr | Hidrofil mikrobiális cellulóz nanorostokat tartalmazó hordozóanyag (gél) a bélnyálkahártya állapotának javítására |
EP3791864A1 (en) * | 2019-09-13 | 2021-03-17 | UPM-Kymmene Corporation | Method for preparing pharmaceutical composition and pharmaceutical composition |
EP3791858A1 (en) | 2019-09-13 | 2021-03-17 | UPM-Kymmene Corporation | Injectable pharmaceutical formulation |
BR102020007749A2 (pt) * | 2020-04-17 | 2021-11-03 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação controlada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da endometriose |
WO2022118104A1 (en) | 2020-12-01 | 2022-06-09 | 3M Innovative Properties Company | Article for storage of bacteriophages and method thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04243819A (ja) | 1991-01-25 | 1992-08-31 | Grelan Pharmaceut Co Ltd | 徐放性製剤 |
US5405953A (en) * | 1993-08-03 | 1995-04-11 | Biocontrol Incorporated | Microfibrillated oxycellulose |
JP4308336B2 (ja) * | 1997-03-14 | 2009-08-05 | 株式会社日本吸収体技術研究所 | ミクロフィブリル状微細繊維構造体およびその製造方法 |
AU2001283107A1 (en) | 2000-09-14 | 2002-03-26 | University Of Iowa Research Foundation | Powdered/microfibrillated cellulose |
JP2006160627A (ja) * | 2004-12-03 | 2006-06-22 | Kyowa Hakko Kogyo Co Ltd | 時限放出化方法 |
JP2006160626A (ja) | 2004-12-03 | 2006-06-22 | Kyowa Hakko Kogyo Co Ltd | 徐放化方法 |
WO2007027849A2 (en) | 2005-08-31 | 2007-03-08 | Board Of Regents, The University Of Texas System | Multiribbon nanocellulose as a matrix for wound healing |
EP2545976B1 (en) * | 2006-02-13 | 2016-08-03 | Donaldson Company, Inc. | Web comprising fine fiber and reactive, adsorptive or absorptive particulate |
CN101172164A (zh) * | 2006-11-03 | 2008-05-07 | 中国科学院化学研究所 | 可生物降解及吸收的生物高分子纳米纤维膜材料及其制法和用途 |
US8287692B2 (en) | 2007-12-28 | 2012-10-16 | Nippon Paper Industries Co., Ltd. | Processes for producing cellulose nanofibers |
US20100159046A1 (en) | 2008-12-19 | 2010-06-24 | Xylos Corporation | Minimal tissue attachment implantable materials |
FI20095638A0 (fi) | 2009-06-09 | 2009-06-09 | Valtion Teknillinen | Hydrofobiineja aktiivisten aineiden dispergointiin |
FI123988B (fi) | 2010-10-27 | 2014-01-31 | Upm Kymmene Corp | Soluviljelymateriaali |
US8758826B2 (en) | 2011-07-05 | 2014-06-24 | Wet Inc. | Cannabinoid receptor binding agents, compositions, and methods |
-
2011
- 2011-11-15 FI FI20116138A patent/FI130619B/fi active
-
2012
- 2012-11-15 WO PCT/FI2012/051121 patent/WO2013072563A1/en active Application Filing
- 2012-11-15 EP EP12799232.9A patent/EP2779996B1/en active Active
- 2012-11-15 JP JP2014541721A patent/JP6178329B2/ja active Active
- 2012-11-15 US US14/358,141 patent/US11389537B2/en active Active
-
2015
- 2015-03-23 HK HK15102889.3A patent/HK1202418A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP2779996A1 (en) | 2014-09-24 |
EP2779996C0 (en) | 2024-04-10 |
FI20116138L (fi) | 2013-05-16 |
FI130619B (fi) | 2023-12-15 |
JP2014533296A (ja) | 2014-12-11 |
EP2779996B1 (en) | 2024-04-10 |
WO2013072563A1 (en) | 2013-05-23 |
US11389537B2 (en) | 2022-07-19 |
US20140322327A1 (en) | 2014-10-30 |
JP6178329B2 (ja) | 2017-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1202418A1 (en) | Drug delivery system for sustained delivery of bioactive agents | |
HK1206634A1 (en) | Vehicles for controlled delivery of different pharmaceutical agents | |
SG10201508662SA (en) | Methods for drug delivery | |
EP2683431A4 (en) | DRUG DELIVERY SYSTEM | |
HK1205928A1 (en) | Ocular drug delivery system | |
PL2654864T3 (pl) | System dostarczania leku | |
BR112013018828A2 (pt) | sistemas de distribuição de droga | |
EP2707146A4 (en) | NOZZLES FOR NASAL DRUG DELIVERY | |
HK1213480A1 (zh) | 用於持續釋放蛋白質的生物可降解的藥物遞送系統 | |
PL3542851T3 (pl) | Wszczepialne urządzenia do dostarczania środków biologicznie czynnych | |
HUE062316T2 (hu) | Gyógyszer-adagolási technológia | |
EP2682075A4 (en) | STENT PLACEMENT SYSTEM | |
EP2776091A4 (en) | METHODS FOR DELIVERY OF VISCOUS MEDICINAL TREATMENTS | |
HRP20181316T1 (hr) | Tehnologija isporuke lijeka | |
ZA201309156B (en) | Drug delivery system | |
EP2689753A4 (en) | STENT DELIVERY SYSTEM | |
IL227352A0 (en) | A system for ocular administration of a drug | |
IL236757A0 (en) | A device for administering a drug with retention in the digestive system | |
EP2679202A4 (en) | STENT PLACEMENT SYSTEM | |
EP2717802A4 (en) | RECOVERABLE STENT DISPENSING SYSTEM | |
GB201110632D0 (en) | Drug delivery formulations | |
EP2896401A4 (en) | TARGETED ACTIVE AGGREGATION SYSTEM FOR HEAVY-DUTY ACTIVE SUBSTANCE | |
EP2768488A4 (en) | TWO-PHASE PHARMACEUTICAL DELIVERY SYSTEM | |
GB201018750D0 (en) | Drug delivery system | |
GB201121693D0 (en) | Medicament delivery technology |